Navigation Links
Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen's Clinical and Scientific Advisory Board
Date:10/7/2015

SAN FRANCISCO, Oct. 7, 2015 /PRNewswire/ -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS), today announced that Maurizio Fava, MD, a world renowned expert in depressive disorders and psychopharmacology, has joined the Company's Clinical and Scientific Advisory Board, effective immediately.  Dr. Fava is Director of the Division of Clinical Research of the Massachusetts General Hospital (MGH) Research Institute, Executive Vice Chair, Department of Psychiatry at MGH, and Executive Director of the MGH Clinical Trials Network and Institute (CTNI), as well as Slater Family Professor of Psychiatry at Harvard Medical School. He co-developed, with Dr. David Schoenfeld, Professor of Biostatistics at the Harvard School of Public Health, a novel, patented clinical trial design which increases the probability of detecting a positive drug response, while markedly reducing sample size requirements for the trial, by reducing the potentially high placebo response sometimes found in depression, and other, clinical trials.

"We are honored to welcome Dr. Fava to our Clinical and Scientific Advisory Board," stated Shawn Singh, Chief Executive Officer of VistaGen.  His leading-edge expertise and guidance will make a significant impact on our clinical development of AV-101 as a new generation, orally-available prodrug candidate for the treatment of Major Depressive Disorder (MDD) and other CNS indications with high unmet need."

Commenting on his appointment, Dr. Fava noted, "I am pleased to join VistaGen's Clinical and Scientific Advisory Board. MDD is a pervasive, debilitating condition which is growing in incidence and, as a result, is a major global health concern. Given the limitations inherent in currently available medications for MDD, including selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), there exists an urgent need for development of new, alternative therapies involving a different mechanism of action to treat this patient population."

Dr. Fava founded and was Director of the MGH Depression Clinical and Research Program (DCRP) from 1990 until 2014. Under his direction, the DCRP became one of the most highly regarded depression programs in the United States. Dr. Fava was co-Principal Investigator, with Dr. A. John Rush, of the largest clinical trial ever conducted in depression, STAR*D, whose findings were published in journals such as the New England Journal of Medicine (NEJM) and the Journal of the American Medical Association (JAMA). Dr. Fava recently served as President of the American Society of Clinical Psychopharmacology (ASCP).

During his career, Dr. Fava has authored or co-authored more than 600 original articles published in medical journals with international circulation. The citation impact of Dr. Fava's work is extremely high, as his articles have been cited more than 40,000 times in the literature.  He has edited eight books, published more than 50 chapters and 600 abstracts, and has given more than 350 presentations at national and international meetings. He is the recipient of several awards, and is on the editorial board of five international medical journals.

About VistaGen Therapeutics
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat depression, cancer and diseases and disorders involving the central nervous system (CNS). VistaGen's AV-101 is a new generation orally-available NMDAR GlyB antagonist in Phase 2 clinical development for Major Depressive Disorder. Based on preclinical studies, AV-101 may also have potential as a treatment for other CNS-related conditions, including chronic neuropathic pain and epilepsy, as well as neurodegenerative diseases such as Parkinson's disease and Huntington's disease. VistaGen is also using its pluripotent stem cell technology platform for potential commercial applications focused on producing proprietary new chemical entities (NCEs) through drug rescue and regenerative therapies for diseases and conditions related to blood, cartilage, heart and liver cells. For additional information, please visit www.VistaGen.com.

Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the VistaGen's successful Phase 2 clinical development of AV-101 in MDD, its stem cell technology-based drug rescue activities, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the foregoing activities. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE VistaGen Therapeutics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Aptuit Names Dr. Maurizio Denaro As General Manager In Verona, Italy
2. Cadence, Inc. Acquires New Capabilities, Expands Internationally
3. Internationally Renowned Researcher From NYU Langone Medical Center Elected To The National Academy Of Sciences
4. SCILEX Pharmaceuticals Announces Appointments of Internationally Recognized Industry Experts
5. Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCanas Chief Scientific Officer
6. 3D Printing, the Disruptive Technology for World Manufacturing has a New Patent Granted to Renowned Inventor Donald Spector
7. Health eVillages Welcomes Five Renowned Executives to Advisory Board
8. TesoRx Closes $10M in Funding, Secures Key Patent and Hires Renowned Urologist as Chief Medical Officer
9. UE Systems Renowned "Ultrasound World" Conference Celebrates its 11th Year
10. Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board
11. World Renowned Inventor Continues To Break Boundaries With Latest Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/5/2017)... -- The Cincinnati location of Diplomat ... DPLO), has been awarded a Top Workplaces 2017 ... are based on an employee survey administered by WorkplaceDynamics, LLC, ... The survey measures several aspects of workplace culture, including alignment, ... ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... If the devil is in ... red these days. According to recent estimates, 75 – 80% of the medical ... Some studies point to Electronic Health Records (EHR) with automated features designed to ...
(Date:6/25/2017)... CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music video ... above footage and sound in the timeline and write in the lyrics to any song. ... flying back out. Each line of the text can be added modularly for optimal control. ...
(Date:6/25/2017)... , ... June 25, 2017 , ... With a heatwave currently bearing down on Northern ... out at the pool. Being swimsuit ready is easy with laser hair removal. , ... again can be a burdensome routine when all you want to do is get out, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation ... significant harm to people with all chronic conditions, including mental illnesses, while increasing ... place the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it ...
Breaking Medicine News(10 mins):